Disease · MONDO_0005921

Plasmodium vivax malaria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Plasmodium vivax malaria. Diseases, record MONDO_0005921. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005921

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Plasmodium vivax malaria; Open Targets
Open Targets ID: MONDO_0005921; Open Targets
Other names: Malaria by Plasmodium vivax, Malaria, Vivax, Vivax malaria (disorder), Vivax malaria [benign tertian], vivax malaria; Open Targets
Disease Ontology: DOID:12978; Disease Ontology
MeSH: D016780; MeSH
NCI Thesaurus: C34800; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 28 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAFENOQUINE	CHEMBL298470	Small molecule	Approval	TTD	14	13	13	Drugs and targets
MEFLOQUINE HYDROCHLORIDE	CHEMBL535650	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TAFENOQUINE SUCCINATE	CHEMBL2364635	Small molecule	Approval	FDA	1	0	0	Drugs and targets
PRIMAQUINE	CHEMBL506	Small molecule	Phase 3	ClinicalTrials.gov	31	31	31	Drugs and targets
CHLOROQUINE	CHEMBL76	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
ARTESUNATE	CHEMBL361497	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
ARTENIMOL	CHEMBL307261	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
PIPERAQUINE	CHEMBL303933	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
PYRIMETHAMINE	CHEMBL36	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
AMODIAQUINE	CHEMBL682	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials55

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01376167	Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse	Phase 2	851	2018-04-23	Malaria, Vivax	CHLOROQUINE, PRIMAQUINE, TAFENOQUINE	Its record names the disease	ClinicalTrials.gov
NCT00440999	Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria	Phase 3	456	2021-09-20	Malaria	ARTESUNATE, CHLOROQUINE, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov
NCT03610399	Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil	Not applicable	257	2021-08-09	P Vivax, Malaria, Vivax	CHLOROQUINE, PRIMAQUINE	Its record names the disease	ClinicalTrials.gov
NCT02216123	Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria	Phase 3	251	2018-05-16	Malaria, Vivax	PRIMAQUINE, TAFENOQUINE	Its record names the disease	ClinicalTrials.gov
NCT04222088	TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014		159	2023-02-23	Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence	ARTEMETHER, CHLOROQUINE, LUMEFANTRINE, LUMEFANTRINE CO-ARTEMETHER, PRIMAQUINE	Its record names the disease	ClinicalTrials.gov
NCT02802501	Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria	Phase 3	150	2020-07-24	Malaria, Vivax	ARTENIMOL, PIPERAQUINE, PRIMAQUINE, TAFENOQUINE	Its record names the disease	ClinicalTrials.gov
NCT01290601	Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults	Phase 2	70	2018-01-25	Malaria, Plasmodium Vivax	CHLOROQUINE, PRIMAQUINE, TAFENOQUINE	Its record names the disease	ClinicalTrials.gov
NCT02563496	A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria	Phase 2	60	2020-11-02	Malaria, Vivax	TAFENOQUINE	Its record names the disease	ClinicalTrials.gov
NCT01753323	Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection	Phase 2	43	2015-08-19	Malaria	GANAPLACIDE	Its record names the disease	ClinicalTrials.gov
NCT04368910	Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria	Phase 3	30	2022-01-26	Malaria	ARTESUNATE, CHLOROQUINE, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 55

See all 55 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pyronaridine Artesunate vs Chloroquine: deaths from any cause	2 of 228	0 of 228	456	NCT00440999	Trial comparisons
Pyronaridine Artesunate vs Chloroquine: serious adverse events	2 of 228	0 of 228	456	NCT00440999	Trial comparisons
TQ+CQ vs PQ+CQ: Number of Participants With P. Falciparum	4 of 166	3 of 85	251	NCT02216123	Trial comparisons
TQ+CQ vs PQ+CQ: Number of Participants With Recrudescence	0 of 166	0 of 85	251	NCT02216123	Trial comparisons
TQ+CQ vs PQ+CQ: deaths from any cause	0 of 166	0 of 85	251	NCT02216123	Trial comparisons
TQ+CQ vs PQ+CQ: serious adverse events	6 of 166	1 of 85	251	NCT02216123	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: deaths from any cause	0 of 84	0 of 75	159	NCT04222088	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events	0 of 84	0 of 75	159	NCT04222088	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Adequate Clinical and Parasitological Response (ACPR)	74 of 75	72 of 74	149	NCT04222088	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Early Treatment Failure (ETF)	0 of 75	0 of 74	149	NCT04222088	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials60

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30698522	RESULT	1	PubMed
29398388	RESULT	1	PubMed
26654101	RESULT	1	PubMed
23212366	RESULT	1	PubMed
22531245	RESULT	1	PubMed
21267072	RESULT	1	PubMed
18171245	RESULT	1	PubMed
17519409	RESULT	1	PubMed
42575554	DERIVED	1	PubMed
42114535	DERIVED	1	PubMed

1 to 10 of 60

See all 60 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005921

GET https://conductscience.org/api/diseases/v1/MONDO_0005921/drugs?page=2

API reference For AI assistants